Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts

Nina H. Pipalia, Casey C. Cosner, Amy Y. Huang, Anamitra Chatterjee, Pauline Bourbon, Nathan Farley, Paul Helquist, Olaf Wiest, Frederick R. MaxfieldProceedings of the National Academy of Sciences 2011 · DOI

TL;DR

This paper demonstrates that certain histone deacetylase inhibitors (HDACi) can effectively reverse cholesterol accumulation in human cells with Niemann-Pick type C1 (NPC1) disease. This breakthrough offers a promising new therapeutic avenue for NPC disease, as the most effective compound, LBH589 (panobinostat), is already in clinical trials for cancer and can cross the blood-brain barrier.

What Problem Does This Paper Address?

Niemann-Pick type C (NPC) disease is a severe, fatal neurodegenerative disorder characterized by the abnormal buildup of cholesterol and other lipids within cellular lysosomes. This lipid accumulation disrupts normal cellular function, leading to progressive damage in the brain and other organs. The disease is primarily caused by mutations in either the NPC1 or NPC2 genes, which are crucial for transporting cholesterol out of lysosomes. Current treatments, like miglustat, can slow disease progression but do not reverse the underlying damage. This study aims to identify novel therapeutic strategies that can correct the fundamental cholesterol trafficking defect in NPC disease, specifically focusing on the common NPC1 mutations.

Methods

The researchers utilized human fibroblast cell lines derived from patients with NPC disease, specifically focusing on cells with mutations in the NPC1 gene (GM03123 and GM18453) and a control cell line with a mutation in the NPC2 gene (GM18445). They employed a panel of six small molecule histone deacetylase inhibitors (HDACi) with varying potencies and selectivities, including commercially available drugs like SAHA and newly synthesized compounds.

The core experimental technique involved treating these cell lines with different concentrations of HDACi for varying durations (4 to 72 hours). Following treatment, cellular cholesterol accumulation in late endosomes/lysosomes (LE/Ls) was quantified using filipin staining, a fluorescent dye that binds specifically to unesterified cholesterol. This staining was visualized and analyzed using automated microscopy.

To investigate the underlying mechanisms, the researchers also performed Western blot analysis to assess NPC1 protein expression levels and SREBP2 processing, a key regulator of cholesterol metabolism. Additionally, they conducted Dil-LDL uptake assays to measure cholesterol import and ACAT assays to evaluate cholesterol esterification.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell culture experiments using established human fibroblast cell lines.

Key Insights and Ideas

  • HDACi as a potential NPC therapy: The most striking finding is that HDAC inhibitors can dramatically reverse the cholesterol accumulation phenotype in NPC1 mutant cells, bringing it close to normal levels.
  • NPC1-specific effect: The HDACi treatment was effective in NPC1 mutant cells but not in NPC2 mutant cells, suggesting a specific mechanism targeting the NPC1 pathway rather than a general bypass of lysosomal function.
  • NPC1 protein upregulation: A key mechanism appears to be the increase in NPC1 protein expression, which may allow the mutant protein to function more effectively in cholesterol efflux.
  • Implication for other NPC1 mutations: The success with the common NPC1 I1061T mutation suggests that HDACi could potentially benefit a broader range of NPC patients with different NPC1 mutations.
  • Blood-brain barrier penetration: The identification of LBH589 (panobinostat) as a potent and orally available HDACi that crosses the blood-brain barrier is a significant step towards developing a viable treatment for the neurological aspects of NPC disease.

Key Results

  • Dramatic cholesterol reduction: HDACi treatment, particularly with LBH589 (40 nM) and TSA (120 nM), restored cholesterol homeostasis in cultured NPC1 mutant fibroblasts to near-normal levels within 72 hours.
  • Potency of LBH589: LBH589 was the most potent inhibitor, correcting the NPC1 phenotype with an EC50 below 5 nM.
  • NPC1 protein increase: Western blot analysis showed increased NPC1 protein levels in HDACi-treated NPC1 mutant cells (GM03123 and GM18453) compared to untreated controls.
  • SREBP2 processing normalization: HDACi treatment reduced the proteolytic processing of SREBP2, consistent with improved cholesterol delivery to the ER.
  • ACAT activity increase: LBH589 treatment led to a 2.5-fold increase in ACAT-mediated cholesterol esterification in NPC1 mutant cells.
  • Ineffectiveness in NPC2 mutants: HDACi treatment had no significant effect on cholesterol accumulation in NPC2 mutant fibroblasts.
  • HDAC1/2 as likely targets: Isoform selectivity analysis suggested that HDAC1 and/or HDAC2 are likely targets for the observed therapeutic effect.

Limitations and Future Work

  • Mechanism complexity: While increased NPC1 expression is implicated, the precise mechanisms by which HDACi achieve this and other effects (like SREBP2 processing and ACAT activity) require further investigation. The relative contributions of increased NPC1 synthesis versus improved protein processing remain to be fully elucidated.
  • Isoform selectivity: While HDAC1/2 are suggested targets, the exact contribution of other HDAC isoforms to the observed phenotype correction is not definitively established.
  • Cell type specificity: The study was conducted using fibroblast cell lines. Further research is needed to confirm these findings in other cell types, particularly neurons, which are critically affected in NPC disease.
  • In vivo studies: The authors highlight that further studies in animal models of NPC disease are a promising direction to explore the therapeutic potential of HDACi, especially LBH589, given its blood-brain barrier permeability.
  • Clinical translation: While LBH589 is in clinical trials for cancer, its efficacy and safety specifically for NPC disease in humans would require dedicated clinical trials.

Summary updated

Abstract

Niemann-Pick type C (NPC) disease is predominantly caused by mutations in the NPC1 protein that affect intracellular cholesterol trafficking and cause accumulation of unesterified cholesterol and other lipids in lysosomal storage organelles. We report the use of a series of small molecule histone deacetylase (HDAC) inhibitors in tissue culture models of NPC human fibroblasts. Some HDAC inhibitors lead to a dramatic correction in the NPC phenotype in cells with either one or two copies of the NPC1(I1061T) mutation, and for several of the inhibitors, correction is associated with increased expression of NPC1 protein. Increased NPC1(I1061T) protein levels may partially account for the correction of the phenotype, because this mutant can promote cholesterol efflux if it is delivered to late endosomes and lysosomes. The HDAC inhibitor treatment is ineffective in an NPC2 mutant human fibroblast line. Analysis of the isoform selectivity of the compounds used implicates HDAC1 and/or HDAC2 as likely targets for the observed correction, although other HDACs may also play a role. LBH589 (panobinostat) is an orally available HDAC inhibitor that crosses the blood-brain barrier and is currently in phase III clinical trials for several types of cancer. It restores cholesterol homeostasis in cultured NPC1 mutant fibroblasts to almost normal levels within 72 h when used at 40 nM. The findings that HDAC inhibitors can correct cholesterol storage defects in human NPC1 mutant cells provide the potential basis for treatment options for NPC disease.
BibTeX
@inproceedings{pipalia2011histone,
  author = {Nina H. Pipalia and Casey C. Cosner and Amy Y. Huang and Anamitra Chatterjee and Pauline Bourbon and Nathan Farley and Paul Helquist and Olaf Wiest and Frederick R. Maxfield},
  title = {{Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2011},
  doi = {10.1073/pnas.1014890108},
}
Figure